

13<sup>th</sup> January 2025

**BSE Limited**

1<sup>st</sup> Floor, New Trading Ring,  
Rotunda Building, P.J. Towers,  
Dalal Street, Fort,  
Mumbai- 400 001  
BSE Scrip Code: 500302

**National Stock Exchange of India Limited**

Exchange Plaza, 5th Floor,  
Plot No. C/1, G-Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai - 400 051  
NSE Symbol: PEL

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') – [Deferred Consideration for sale of stake in a subsidiary]**

Dear Sir / Madam,

This is to inform you that the Company vide letter dated 26<sup>th</sup> June 2018 (attached as appendix) had informed the Stock Exchanges about the divestment of one of its step-down subsidiaries (Piramal Imaging SA) to Alliance Medical Acquisitionco Limited (AMAL). Vide the said letter, the Company had also informed about the consideration agreed to be paid for such divestment which included deferred consideration which would be contingent on future profits of Piramal Imaging SA and its subsidiaries (the "Imaging Group").

We wish to inform you that the Company has now been informed by Life Healthcare Group Holdings Limited (Life Healthcare), (part of the group that acquired Piramal Imaging SA from the Company in 2018), that they have entered into binding agreements for sale of Life Molecular Imaging Limited, a member of the Imaging Group, which agreement is subject *inter alia* to receipt of the approval of the shareholders of Life Healthcare and various regulatory and other approvals ("Proposed Transaction"). On completion of the Proposed Transaction, the Company (through its subsidiary) will become eligible to receive an estimated amount of USD 140 million (subject to final closing adjustments), expected to be received by the Company in FY 2026. The Company may also receive further amounts in subsequent years from any eligible profits and future earnouts relating to the Imaging Group, subject to a maximum of USD 200 million (inclusive of the above USD 140 million).

The link to the announcement of the Proposed Transaction is as follows:

[https://www.lifehealthcare.co.za/media/4055/project-eagle\\_final-terms-announcement\\_13-january-2025-final.pdf](https://www.lifehealthcare.co.za/media/4055/project-eagle_final-terms-announcement_13-january-2025-final.pdf)

Kindly take the above information on your record.

Thanking you,

Yours faithfully,  
For **Piramal Enterprises Limited**

**Bipin Singh**  
Company Secretary

**Encl.:** as above

**Piramal Enterprises Limited**

CIN: L24110MH1947PLC005719

Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai 400 070 India  
Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India  
Email Id: [complianceofficer.pel@piramal.com](mailto:complianceofficer.pel@piramal.com) | T +91 22 3802 3084/3083/3103 F +91 22 3802 3084

[piramalenterprises.com](http://piramalenterprises.com)

26<sup>th</sup> June, 2018

**BSE Limited,**  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Bldg., P.J. Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra-Kurla Complex,  
Mumbai – 400 051.

**Ref: BSE SCRIP CODE – 500302, 912459**  
**NSE SYMBOL - PEL**

**Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,


In accordance with Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that on 25<sup>th</sup> June, 2018, Piramal Holdings (Suisse) SA (a wholly owned subsidiary of Piramal Enterprises Limited) has entered into a definitive agreement thereby divesting its entire stake in Piramal Imaging SA ('PISA'), its subsidiary, to Alliance Medical Acquisitionco Limited ('Alliance'). Consequent to the divestment, Piramal Imaging Limited and Piramal Imaging GmbH, wholly-owned subsidiaries of PISA will also become subsidiaries of Alliance and cease to be step-down subsidiaries of PEL.

The details as required under Regulation 30 of the SEBI Regulation read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in Annexure A to this letter.

Thank you.

Yours faithfully,

For **Piramal Enterprises Limited**



**Chanda Makhija Thadani**  
Assistant Company Secretary



**Piramal Enterprises Limited**

CIN : L24110MH1947PLC005719

Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Mag, Kurla (West), Mumbai 400 070 India  
Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India

T +91 22 3802 3084/3083/3103 F +91 22 3802 3084

[piramal.com](http://piramal.com)

**ANNEXURE A**

<b>Sr. No.</b>	<b>Details of the Events that need to be Provided</b>	<b>Information of such event(s)</b>				
a.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	<p>This is a step-down subsidiary of Piramal Enterprises Limited. It is neither a unit nor a division.</p> <p>Details for the financial year ended 31<sup>st</sup> March, 2018:</p> <p style="text-align: right;">Rs. In Crores</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <tr> <td>Revenue from operations</td> <td style="text-align: right;">127.48</td> </tr> <tr> <td>Net Worth</td> <td style="text-align: right;">(818.65)</td> </tr> </table>	Revenue from operations	127.48	Net Worth	(818.65)
Revenue from operations	127.48					
Net Worth	(818.65)					
b.	Date on which the agreement for sale has been entered into	The Share Purchase Agreement ('SPA') has been executed on 25 <sup>th</sup> June, 2018				
c.	The expected date of completion of sale/disposal	On or about 25 <sup>th</sup> June, 2018				
d.	Consideration received from such sale/disposal	Base consideration of USD 1 plus USD 1,177,682 towards working capital adjustment on completion of the sale, plus deferred consideration which would be contingent on future profits over a period not exceeding 10 years from the date of completion of the Transaction				
e.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	<p>The Buyer is Alliance Medical Acquisitionco Limited, a Private Limited Company incorporated and registered in Warwick, United Kingdom.</p> <p>The Buyer does not belong to the promoter/ promoter group/ promoter group companies</p>				
f.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	No, this is not a Related Party Transaction				
g.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not applicable				


**Piramal Enterprises Limited**

CIN : L24110MH1947PLC005719

 Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai 400 070 India  
 Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India

T +91 22 3802 3084/3083/3103 F +91 22 3802 3084

[piramal.com](http://piramal.com)